Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08DKA
|
|||
| Former ID |
DNC000874
|
|||
| Drug Name |
Levcromakalim
|
|||
| Synonyms |
Levcromakalim; Lemakalim; Cromakalim; (-)-Cromakalim; 94535-50-9; Levcromakelim; BRL 38227; BRL-38227; UNII-RW7PN4BLDJ; RW7PN4BLDJ; CHEMBL100; BRN 3622889; MLS000069770; CHEBI:6436; Cromakalime [French]; Cromakalimum [Latin]; Cromakalim, (3S-trans)-Isomer; SMR000058880; (3S,4R)-3-Hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-chromancarbonitrile; DSSTox_RID_81051; DSSTox_CID_25677; DSSTox_GSID_45677; 94470-67-4; Cromakalimum; Cromakalime; BRL-34915; BRL 34915; 2H-1-Benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-o
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Discontinued in Preregistration | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H18N2O3
|
|||
| Canonical SMILES |
CC1(C(C(C2=C(O1)C=CC(=C2)C#N)N3CCCC3=O)O)C
|
|||
| InChI |
1S/C16H18N2O3/c1-16(2)15(20)14(18-7-3-4-13(18)19)11-8-10(9-17)5-6-12(11)21-16/h5-6,8,14-15,20H,3-4,7H2,1-2H3/t14-,15+/m1/s1
|
|||
| InChIKey |
TVZCRIROJQEVOT-CABCVRRESA-N
|
|||
| CAS Number |
CAS 94535-50-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
13862, 7849444, 10226030, 11533011, 12012635, 12013378, 14799903, 14848970, 44424225, 49888959, 50104830, 56422898, 57335653, 58106920, 78187575, 85787605, 88531708, 103163435, 103175166, 103923014, 104231653, 104410296, 104829454, 124800687, 129321997, 134340178, 135049671, 135697973, 137248936, 142309865, 144204499, 144207130, 162022816, 162249675, 170466479, 179151459, 184545850, 198959342, 198975023, 223440164, 223454350, 224852619, 226493664, 241182377, 252351249
|
|||
| ChEBI ID |
CHEBI:6436
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Potassium channel unspecific (KC) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000036) | |||
| REF 2 | The potassium channel opener levcromakalim causes expansive remodelling of experimental vein grafts. J Vasc Surg. 2006 Jul;44(1):159-65. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.